Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in IBRX — ImmunityBio, Inc.

CIK 1423053 MIAMI, FL
Back to IBRX Full portfolio

Position in IBRX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$2,343,782
+$948,727 QoQ
Shares Held
305,578
-56.6% QoQ
Ownership
0.029%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
21 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in IBRX Over Time

Shares Held

Position Value (USD)

Derivatives in IBRX

reported options exposure · as of Mar 31, 2026
CallValue
$22,060,454
CallShares
2,876,200
PutValue
$14,987,947
PutShares
1,954,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,783,571,443 across 373 Biotechnology names. IBRX ranks #187 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in IBRX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $2,343,782 305,578
2026-03-31 $22,060,454 2,876,200
2026-03-31 $14,987,947 1,954,100
2025-12-31 $675,180 341,000
2025-12-31 $1,395,055 704,574
2025-12-31 $1,239,876 626,200
2025-09-30 $1,231,230 500,500
2025-09-30 $1,305,030 530,500
2025-09-30 $2,781,639 1,130,748
2025-06-30 $1,157,640 438,500
2025-06-30 $2,075,634 786,225
2025-06-30 $1,097,184 415,600
2025-03-31 $1,454,131 483,100
2025-03-31 $1,439,751 478,323
2025-03-31 $1,166,074 387,400
2024-12-31 $183,682 71,751
2024-12-31 $1,856,768 725,300
2024-12-31 $624,640 244,000
2024-09-30 $602,640 162,000
2024-09-30 $1,877,484 504,700
2024-09-30 $1,175,929 316,110
2024-06-30 $3,213,720 508,500
2024-06-30 $2,133,000 337,500
2024-06-30 $1,371,300 216,978
2024-03-31 $2,775,753 516,900
2024-03-31 $2,381,058 443,400
2024-03-31 $257 48
2023-12-31 $478,908 95,400
2023-12-31 $1,791,638 356,900
2023-09-30 $432,302 255,800
2023-09-30 $284,765 168,500
2023-06-30 $758,106 272,700
2023-06-30 $582,132 209,400
2023-03-31 $484,484 266,200
2023-03-31 $153,790 84,500
2023-03-31 $445,392 244,721
2022-12-31 $1,548,378 305,400
2022-12-31 $775,811 153,020
2022-12-31 $397,995 78,500
2022-09-30 $1,025,808 206,400
2022-09-30 $2,724,325 548,154
2022-09-30 $384,181 77,300
2022-06-30 $2,894,089 777,981
2022-06-30 $268,212 72,100
2022-06-30 $518,196 139,300
2022-03-31 $498,729 88,900
2022-03-31 $1,906,619 339,861
2022-03-31 $523,413 93,300
2021-12-31 $183,244 30,139
2021-12-31 $592,800 97,500

Report a Problem

Category
Description
Email (optional, for follow-up)